Professional
Added to YB: 2025-06-11
Pitch date: 2025-06-10
HROW [bullish]
Harrow, Inc.
+50.26%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
Market Cap
$1.6B
Pitch Price
$31.32
Price Target
63.00 (+34%)
Dividend
N/A
EV/EBITDA
38.20
P/E
-324.83
EV/Sales
7.29
Sector
Pharmaceuticals
Category
growth
Show full summary:
William Blair initiated coverage of Harrow $HROW with an Outperform rating and $63 fair value estimate
HROW: William Blair initiates Outperform rating, $63 PT. Ophthalmic pharma expanding from compounding to branded drugs portfolio with higher growth/margins. Vevye Access for All program accelerating growth, early in adoption curve. Triesence reintroduction adds complementary growth driver.
Read full article (1 min)